RxDoctor Payments Data

Jiwan Thapa, MD

Nephrology · Minneapolis, MNNPI 1518123355

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,574 of the $2,590 with a category attached, or 60.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 79.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $2,061, more than ten times the $201 reported in 2019.

$2,590in general payments, 2019–2025

Across 38 payments — averaging $68.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$135
  • Nxstage Medical, Inc.$93
  • Akebia Therapeutics Inc$58
  • Travere Therapeutics, Inc.$43
  • Vertex$42
  • plus $158 from 7 others

What the payments were for

  • Travel & lodging$1,57461%
  • Food & beverage$91435%
  • Education$1034%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,590 in reported general payments places this provider in the 85th percentile of 208 nephrology providers in Minnesota.

See all nephrology providers in Minnesota

Medicare billing

Part B allowed, 2024
$80,860
Medicare patients
193
Services billed
875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$8,773
LokelmaSodium Zirconium Cyclosilicate12$4,764
ClinolipidFat Emulsion/Olive/Soy/Phospho15$4,689
Sevelamer Carbonate27$2,822
Calcium Acetate21$2,158
Bumetanide22$1,051
Carvedilol27$570
Hydralazine Hcl11$447
Amlodipine Besylate33$437
Torsemide26$411
Potassium Chloride17$358
Allopurinol23$299
Furosemide30$211
Prednisone15$172
Losartan Potassium18$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$41$13,53828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 208 nephrology providers in Minnesota.

Other nephrology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →